| |
| Device | myChoice CDx |
| Generic Name | Cancer-related germline gene mutation detection system |
| Applicant | Myriad Genetic Laboratories, Inc. 320 Wankara Way Salt Lake City, UT 84108 |
| PMA Number | P190014 |
| Supplement Number | S004 |
| Date Received | 07/28/2020 |
| Decision Date | 01/27/2021 |
| Product Code |
PJG |
| Advisory Committee |
Pathology |
| Supplement Type | Normal 180 Day Track |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval for Myriad myChoice® CDx to expand labeling based on SOLO1 study for the treatment of the patients with BRCA mutated advanced ovarian cancer with LYNPARZA (olaparib). |